Navigation Links
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Date:10/21/2009

ond to tumor cells by blocking PS-mediated immunosuppression. Bavituximab is being tested in combination with chemotherapy in Phase II trials in advanced lung cancer and advanced breast cancer. Interim results in these trials have been encouraging, with objective tumor response rates that compare favorably to chemotherapy alone.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(®). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that that the rate of objective tumor response for future trials will not be consistent with the objective tumor response experienced in the Phase II trials and the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy. Factors that could cause actual results to differ materially or otherwise adversely impact the company's a
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
2. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
3. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
5. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
6. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
7. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
8. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
9. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 29, 2014 Electrodes ... potential which can be amplified to diagnose as ... electrodes used in medical devices facilitate the detection ... from muscle cells and neurons of the patients. ... utilize the radiofrequency alternating current to perform minimally ...
(Date:10/30/2014)... BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial ... "During the quarter, we achieved a key ... securing a partner to accelerate the development and commercialization of ... we do not have a commercial presence while also retaining ... the value of PIXUVRI for CTI and help us achieve ...
(Date:10/30/2014)... YORK , Oct. 29, 2014 ... growth through 2013 with the introduction of new ... well-covered in Vaccines: The World Market. The Kalorama ... covering specifically commercialized vaccines and developmental vaccines for ... not only individuals, but also entire communities from ...
Breaking Medicine Technology:Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3
... (Nasdaq: UPI ), a medical device company ... treat voiding dysfunctions, announced today that David Kaysen, Uroplasty,s ... and CFO, will present the Company,s business strategy and ... Conference at 3:30  PM PDT on Tuesday, August 17, ...
... SPRING, Md., Aug. 16 The U.S. Food ... of the drug midodrine hydrochloride, used to treat ... required post-approval studies that verify the clinical benefit ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference 2FDA Proposes Withdrawal of Low Blood Pressure Drug 2FDA Proposes Withdrawal of Low Blood Pressure Drug 3
(Date:10/30/2014)... the DFG Research Center for Regenerative Therapies Dresden - ... for the first time the in vitro growth of ... mouse embryonic stem cells. Correct spatial organization of motor ... was observed., This study has been published online by ... on 30.10.2014 ., For many years Elly Tanaka and ...
(Date:10/30/2014)... Beach, Florida (PRWEB) October 30, 2014 ... Halloween visit to Pompano Beach firefighters, showing that you ... community. , Timothy met firefighters Tracey and Carl ... by Galuppiā€™s Restaurant and the Pompano Beach Chamber of ... outside the fire truck, letting Timothy wear his real ...
(Date:10/30/2014)... San Diego, Calif. (PRWEB) October 30, 2014 ... no longer mutually exclusive concepts in the medical-grade ... focusing on the development of uniquely potent topical ... Skin Health System ( http://www.RefinitySkinScience.com ) with patented ... highest available glycolic acid concentrations (50% and 70%) ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits manager focused ... people save money through its innovative discount card program. ... in the new health care system, the Paramount Rx ... relationship between consumers, businesses and the pharmacy industry. ... today with medical costs is the rising price of ...
(Date:10/30/2014)... By Tara Haelle ... (HealthDay News) -- More than 100 genes have been ... new studies report. And researchers say they are ... overall that may contribute to the disorder. Autism ... by communication and social difficulties and repetitive behaviors. An ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... , CAMBRIDGE, Mass. , ... organization focused on advancing human health through innovation, today ... Business Innovation Research (SBIR) contract from the National Aeronautics ... develop nanoscale diagnostic technologies that facilitate whole health analysis ...
... from mice, scientists from Iowa and Iran have discovered a ... to be rejected by a recipient,s immune system. This strategy, ... 2010 print issue of The FASEB Journal ( ... cells. Once fused, the hybrid cells have DNA from both ...
... produces an extraordinary and dangerous poison. This is the only ... A study carried out at the University of Haifa has ... Has the almond tree developed a unique way of ... of Environmental and Evolutionary Biology and the Department of Science ...
... the process of diagnosing heart conditions. The portable ... with funding from the Engineering and Physical Sciences Research ... to its unprecedented sensitivity to magnetic fluctuations the device ... including heart problems in foetuses, earlier than currently available ...
... ... and downs of the decade. , ... Pennington, NJ (PRWEB) January 28, 2010 -- In good times and in bad, people ... Robinson, Inc., overall attitudes towards Super Bowl advertising have remained strongly positive throughout the economic ...
... 2010 ... information, many more products in an ever expanding market but “simplified buying for the ... ... -- 2010 marks the launch of Décor Grille’s new “ Security Direct ” web ...
Cached Medicine News:Health News:NASA selects DNA Medicine Institute's Nanoscale Diagnostics Technology for Phase II SBIR 2Health News:Stem cell breakthrough: Bone marrow cells are the answer 2Health News:The almond tree's secret weapon 2Health News:The almond tree's secret weapon 3Health News:Breakthrough heart scanner will allow earlier diagnosis 2Health News:Super Bowl Advertising, In Good Times And Bad 2Health News:Super Bowl Advertising, In Good Times And Bad 3Health News:Dcor Grille Leads into the Next Decade with its New Security Web Site 2
... Cement consists of a two ... bone cement liquid within a ... polyethylene bag,containing bone cement powder ... interiors of the blister pack,and ...
... Radiopaque Bone Cement consists of ... sterile,ampule containing bone cement liquid ... a sterile polyethylene bag,containing bone ... pouch. The interiors of the ...
A "doughy" type of bone cement intended for manual application....
... technology, such as a recessed scratch-resistant sapphire ... housings, this arthroscope has superior clarity and ... Steris and steam autoclaving or soaked in ... to fit ACMI, Wolf, Dyonics and Storz ...
Medicine Products: